摘要
年龄相关性黄斑变性(AMD)是目前全球致盲的主要病因之一。抗血管内皮生长因子(Anti-VEGF)疗法已成为新生血管性AMD的一线治疗方案。考虑到抗VEGF药物的费用昂贵,患者需要长期甚至终身接受反复抗VEGF注射治疗,了解真实世界中抗VEGF的治疗情况,对于指导临床实践、改善患者诊疗路径乃至卫生决策都十分重要。近年来基于电子化信息平台的新生血管性AMD数据分析研究向我们展现了不同国家和地区新生血管性AMD的流行病学、真实世界抗VEGF的治疗情况以及医疗支出等,笔者就此作一综述。
Age-related macular degeneration(AMD)is one of the major causes of blindness around the world.Anti-vascular endothelial growth factor(anti-VEGF)therapy has become the first-line therapy for treating neovascular AMD(nAMD).Considering the burden of the high cost of anti-VEGF medicine,long-term and often lifelong repeated injections required of patients,it is important to understand the patterns of anti-VEGF therapy for nAMD patients in real-world settings,which will optimize the delivery of healthcare for nAMD patients,improve clinical pathways and may even help with decision-making in healthcare policy.Recently,data analysis studies on nAMD,based on electronic information platforms,have unveiled the epidemiology of nAMD in different countries and regions,the anti-VEGF therapy patterns in the real world and the medical expenditure related to nAMD.This article reviews research progress in real-world studies on nAMD based on electronic information platforms.
作者
沈梦溪
汪枫桦
孙晓东
Mengxi Shen;Fenghua Wang;Xiaodong Sun(Department of Ophthalmology,Shanghai General Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200080,China;Shanghai Engineering Center for Visual Science and Photomedicine,Shanghai 200080,China;Shanghai Key Laboratory of Fundus Diseases,Shanghai 200080,China)
出处
《中华眼视光学与视觉科学杂志》
CAS
CSCD
2019年第3期237-240,共4页
Chinese Journal Of Optometry Ophthalmology And Visual Science
基金
上海市科学技术委员会(引导)项目基金(16411952900)
国家自然科学基金(81470640)
上海市教育委员会高峰高原学科建设计划(20152229).
